These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14689107)

  • 41. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
    Wald DS; Law M; Morris JK; Bestwick JP; Wald NJ
    Am J Med; 2009 Mar; 122(3):290-300. PubMed ID: 19272490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program.
    Lee HY; Oh BH
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):251-7. PubMed ID: 19296761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Medical treatment of hypertension--what treatment for what patients?].
    Zidek W; Tepel M; van der Giet M
    MMW Fortschr Med; 2004 May; 146(22):31-4. PubMed ID: 15373106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension.
    Antonopoulos S; Kokkoris S; Gerakari S; Mikros S; Nitsotolis T; Vikeli D; Korantzopoulos P; Giannoulis G
    Angiology; 2008; 59(2):230-5. PubMed ID: 18388088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fixed drug combinations in the treatment of hypertension: how to identify the optimal dose.
    Messerli FH; Michalewicz L
    J Hypertens Suppl; 1998 Jan; 16(1):S81-4. PubMed ID: 9534103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical relevance of pharmacological blood pressure lowering mechanisms.
    Lonn E
    Can J Cardiol; 2004 Aug; 20 Suppl B():83B-88B. PubMed ID: 15309210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fifty years of thiazide diuretic therapy for hypertension.
    Moser M; Feig PU
    Arch Intern Med; 2009 Nov; 169(20):1851-6. PubMed ID: 19901136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA
    Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multidrug regimens in moderate & severe hypertension.
    Lee HC; Pettinger WA
    Nebr Med J; 1992 Nov; 77(11):300-9. PubMed ID: 1461323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of recent fixed-dose combination therapies in the management of hypertension.
    Khanna A; Lefkowitz L; White WB
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):477-83. PubMed ID: 18695388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Refractory hypertension--principles of combination therapy].
    Hitzenberger G
    Acta Med Austriaca; 1995; 22(3):43-5. PubMed ID: 8571749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacoeconomic challenges in disease management of hypertension.
    Ambrosioni E
    J Hypertens Suppl; 2001 Sep; 19(3):S33-40. PubMed ID: 11713849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The rationale for drug combinations in the therapy of arterial hypertension].
    Salvetti A; Virdis A; Di Venanzio L
    Ann Ital Med Int; 1993 Oct; 8 Suppl():107S-110S. PubMed ID: 8117517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lessons from antihypertensive drug trials that employed "stepped care": the case for rationalized individualized treatment strategies based on renin system patterns.
    Laragh JH
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1067-72. PubMed ID: 6085369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for the use of very-low-dose combinations as first-line treatment of hypertension.
    Waeber B; Brunner HR
    J Hypertens Suppl; 2001 Nov; 19(4):S3-8. PubMed ID: 11848261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The treatment of arterial hypertension: which drug for which patient?].
    Wafber B; Niederberger M; Nussberger J; Burnier M; Brunner HR
    Schweiz Rundsch Med Prax; 1992 Jan; 81(3):32-6. PubMed ID: 1732999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.